Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01982448 · ClinicalTrials.gov registry record · Phase 2
Cisplatin vs Paclitaxel for Triple Negative Breast Cancer
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 147
- Enrollment target
NCT01982448 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 147 participants.
The verdict
NCT01982448, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 147 participants
- Enrollment target
Study Summary
This is a phase II study randomizing patients with stage I with T1 \> 1.5 cm, stage II or III triple negative breast cancer (TNBC) to preoperative cisplatin versus paclitaxel. The study is designed to evaluate the ability of the Homologous Recombination Deficiency (HRD) assay to predict pathologic response to preoperative chemotherapy.
Interventions
- DRUG Cisplatin
- DRUG Paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 147 participants |
| Start Date | 2014-04 |
| Est. Completion | 2020-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01982448
The ClinicalTrials.gov registry entry for NCT01982448 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 147 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cisplatin is the first listed.
NCT01982448 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01982448 about?
NCT01982448 is a clinical study titled "Cisplatin vs Paclitaxel for Triple Negative Breast Cancer". This is a phase II study randomizing patients with stage I with T1 \> 1.5 cm, stage II or III triple negative breast cancer (TNBC) to preoperative cisplatin versus paclitaxel. The study is designed to evaluate the ability of the Homologous Recombination Deficiency (HRD) assay to predict pathologic r...
What is the current status of trial NCT01982448?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 147 participants. The study started on 2014-04. Estimated completion is 2020-08.
What interventions are being tested in trial NCT01982448?
The interventions under investigation include: Cisplatin (DRUG), Paclitaxel (DRUG).
Who is sponsoring clinical trial NCT01982448?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.